Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO

Laurus Labs Limited (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research & development-driven and fully integrated pharmaceutical and biotech company in India, announcesthat it has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.

Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG.

Shares of Laurus Labs Ltd was last trading in BSE at Rs.667 as compared to the previous close of Rs. 679.6. The total number of shares traded during the day was 157141 in over 5468 trades.

The stock hit an intraday high of Rs. 691.9 and intraday low of 664.5. The net turnover during the day was Rs. 105722287.

Source : Equity Bulls

Keywords